AC Immune Secures CHF 10M Upfront Payment in Amended Lilly Collaboration for Tau Inhibitors

summarizeSummary

AC Immune SA announced an amendment to its collaboration agreement with Eli Lilly, securing a CHF 10 million upfront payment and additional milestones for the development of Tau aggregation inhibitors, with IND-enabling studies commencing soon.

check_boxKey Events

• Upfront Payment Secured

  AC Immune received a CHF 10 million upfront payment from Eli Lilly and Company as part of an amended license and collaboration agreement.

• Amended Collaboration Agreement

  The existing agreement with Eli Lilly for the research and development of Tau aggregation inhibitor small molecules for neurodegenerative diseases was amended, continuing the collaboration.

• Future Milestones & Royalties

  AC Immune remains eligible for over CHF 1.7 billion in potential development, regulatory, and commercial milestones, in addition to tiered low double-digit royalty payments.

• Product Development Progress

  Investigational New Drug (IND)-enabling studies for the Tau Morphomer candidates are expected to commence in the first half of 2026.

auto_awesomeAnalysis

This filing announces a significant amendment to AC Immune's collaboration agreement with Eli Lilly, securing a CHF 10 million upfront payment. This non-dilutive cash infusion represents approximately 4% of AC Immune's current market capitalization, providing substantial financial runway. The continuation and progression of this partnership with a major pharmaceutical company like Eli Lilly, coupled with the imminent start of IND-enabling studies for Tau aggregation inhibitors, signals positive momentum in AC Immune's product development pipeline for neurodegenerative diseases. Investors should view this as a strong validation of AC Immune's Morphomer technology and a de-risking event for its lead candidates.